FDA Clearance Tracker · P810031-S066
Sodium Hyaluronate Ophthalmic Viscoelastic Device (OVD), Healon GV PRO
Last checked: Nov 20, 2026Latest source record: Nov 25, 2020 (this decision)Source: openFDAMethods & limitations
Decided
Nov 25, 2020
Approved
Time to decision
261 days
Received Mar 9, 2020. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P810031-S066
- Device name
- Sodium Hyaluronate Ophthalmic Viscoelastic Device (OVD), Healon GV PRO
- Applicant location
- Irvine, CA
- Received
- Mar 9, 2020
- Decided
- Nov 25, 2020
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P810031
Device type
- Device type
- AID, SURGICAL, VISCOELASTIC (LZP)
- Device class
- Class III
- Regulation
- 21 CFR 886.4275
- Specialty
- Ophthalmology
FDA's approval statement
As written in FDA's record.
Approval for changes in labeling to include a new Warning, modifications to the Device Description and Precautions, and the addition of two surgical techniques for removal of the Healon GV® PRO OVD from the eye.
Source documents
Other decisions for Johnson & Johnson Surgical Vision, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- TECNIS PureSee IOL, Model DEN00V TECNIS PureSee Toric II IOLs, Model DET150, DET225, DET300, DET375PMA supplement
P980040-S176 · Decided Mar 11, 2026 · 223 days after receipt · Panel Track
Device type: intraocular lens (HQL) · Ophthalmology
6 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.